OBJECTIVE-We sought to determine prevalence and likelihood of venous thromboembolism (VTE) among women with and without polycystic ovary syndrome (PCOS).
characteristic of clinical hyperandrogenism, was not included because no ICD-9-CM codes were available for this laboratory value in the database. "Ovulatory dysfunction" was defined by the presence of any 1 of the ICD-9-CM codes for the 626 series, which are codes dealing with disorders of menstruation and other abnormal bleeding from the female genital tract: 626.0, 626.1, 626.2, 626.3, 626.4, 626.5, 626.6, 626.7, 626.8, or 626.9.
"Polycystic ovaries" were defined by ICD-9-CM code 256.4.
Exclusion of other conditions
We excluded women who met the criteria for any of the PCOS phenotypes and had ≥1 of the following conditions: adrenal hyperplasia (255.0 or 255.9), hyperprolactinemia (253. 19 ), or both on any inpatient or outpatient claim. To reduce inaccurate reporting of DVT and PE diagnoses, we restricted outpatient diagnoses to those with a relevant Current Procedural Terminology code (Appendix) and who had a filled prescription for an anticoagulant medication within 90 days of the VTE diagnosis; for an inpatient diagnosis, only 1 appropriate ICD-9-CM code for DVT or PE was required. Diagnosis of VTE was counted only once, regardless of the number of times it was reported in the claims database.
Unique identification numbers were used to track all women longitudinally over the study period. Women were included if they were enrolled in any health plan, even if no health claims were submitted during the 6-year study period.
Covariates
Information on demographic characteristics and clinical comorbid conditions was captured from the claims database: age, geographic region of residence, pregnancy during the time frame of study, oral contraceptive use, diabetes, obesity, metabolic syndrome, thrombophilia (289.81), and history of a VTE (V12.51). Pregnancy was defined as any inpatient hospital admission for a pregnancy-related diagnosis or procedure (V27. 
Data analysis
To calculate VTE prevalence among women with PCOS, the number of VTE cases among women with PCOS was divided by the total number of women among the underlying MarketScan population with PCOS. For the individual phenotypes, prevalence was calculated by dividing the number of women with VTE and the particular PCOS phenotype by the total number of women with that type of PCOS. For women without PCOS, the prevalence of VTE was calculated by dividing the number of women with VTE and no PCOS by the total underlying MarketScan population without PCOS. Differences in the distribution of demographic and comorbid conditions among women with and those without PCOS were assessed using 2-tailed χ 2 tests.
Bivariate analyses were used to compare the distribution of demographic and potential clinical risk factors for VTE among women with and those without PCOS. Multivariate logistic regression analyses also were used to assess the likelihood of a VTE diagnosis among women with and those without PCOS. The final multivariable regression model had only those variables that have been shown to be associated with VTE risk and changed the estimate of the association between VTE and PCOS by >10%. These variables, which we adjusted for, were age, pregnancy during study period, OCP use, region, obesity, and diabetes. We also used logistic regression models to test for interactions between PCOS and the previously cited variables. Age was found to be an effect modifier, so we stratified the analysis by 3 age groups (18-24, 25-34, and 35-45 years). Even though OCP use was not found to be an effect modifier, we stratified the analysis by OCP use because, in 2003, Seaman et al 25 demonstrated an increased risk of VTE among women with acne, hirsutism, or PCOS who used cyproterone acetate in combination with ethinyl estradiol. All data were analyzed and managed using software (SAS, version 9.2; SAS Institute Inc, Cary, NC). All analyses were conducted at a priori significance level (P < .05).
Results

Prevalence of VTE
A total of 12,171,830 women were eligible to be in the study; of these, 23,941 (0.20%) had VTE; among the group with VTE, 14,321 (59.8%) had DVT only, 4967 (20.7%) had PE only, and 4653 (19.4%) had both VTE and PE. The overall prevalence of VTE among the PCOS population was 374.2 per 100,000, while the prevalence of VTE among women without PCOS was 193.8 per 100,000 ( Figure 1 ). Among the phenotypes, women with phenotype D had the highest prevalence of VTE, at 478.9 per 100,000 ( Figure 1 ). Figure 2 displays the prevalence of VTE per 100,000, stratified by age, among women with and those without PCOS. For both cohorts, the prevalence of VTE was highest among women 35-45 years of age ( Figure 2 ).
The characteristics of women with and those without PCOS are shown in Table 1 . Statistically significant differences existed in percentage distributions in VTE frequencies (P <.0001), age (P <.0001), region (P < .0001), presence of metabolic syndrome (P = .0002), obesity (P <.0001), pregnancy (P <.0001), and diabetes (P < .0001). Other significant differences were noted between having inherited thrombophilia (P < .0001) and having used OCPs (P < .0001) ( Table 1 ). There was no significant difference in having a history of VTE (P = .243) between women with and those without PCOS (Table 1) . Table 2 displays the age-stratified association between the PCOS phenotypes and VTE. We found that regardless of age and PCOS phenotype, the odds of having VTE were higher for women with PCOS compared with women without PCOS. We also observed that women 18-24 years of age with PCOS had the highest odds of having VTE (adjusted odds ratio [OR], 3.26; 95% confidence interval [CI], 2.61-4.08) when compared with women 18-24 years of age without PCOS. Lastly, we observed that women 18-24 years of age with phenotype B (hyperandrogenism and polycystic ovaries) had the highest probability of having VTE (adjusted OR, 5.23; 95% CI, 2.88-9.51) when compared with women of the same age without PCOS (Table 2 ).
In Table 3 , we present the adjusted relationships between PCOS phenotypes and VTE when stratified by age and OCP use. We found that women with PCOS still had increased odds of VTE compared with women without PCOS, regardless of age and OCP use. However, when we looked at the unadjusted effect of OCP use on VTE prevalence only among the cohort of women with PCOS (not shown in tables), we observed a protective effect for VTE (OR, 0.8; 95% CI, 0.73-0.97).
Comment
To our knowledge, this is the first study to assess the prevalence of VTE among women with PCOS. We found that the prevalence of VTE was higher among women with PCOS compared with women without PCOS. Similar to findings in other studies, our findings revealed the absolute prevalence of VTE to be highest among older women (34-45 years of age), regardless of PCOS status. 3, 4, 6, 7, 26 Unexpectedly, however, we found that women 18-24 years of age had the highest likelihood of having a VTE diagnosis, meaning that the relative odds of VTE among those who had PCOS compared with those who did not have PCOS was greatest among women 18-24 years of age, even after adjusting for known risk factors (pregnancy, OCP use, region, diabetes, and obesity). In the multivariable logistic regression models, women with PCOS, regardless of phenotype, also had a higher probability of VTE compared with women without PCOS. In addition, we found that women with phenotype B (hyperandrogenism and polycystic ovaries), who were 18-24 years of age, had the highest prevalence of VTE. These findings raise questions about the role of PCOS among younger women and their risk for VTE development.
The nature of our study design makes it difficult to elucidate the reasons for this finding. However, we do speculate that since fertility is optimized between 18-25 years of age, women with PCOS within this age range would likely have elevated production of estrogen and androgens. This boost in hormone production would likely lead to an increase in the derangement with luteinizing hormone, sex hormone-binding globulin, and hyperinsulinemia noted in PCOS. 27 Hyperinsulinemia 28 and lower sex hormone-binding globulin 29 have been shown to impair fibrinolysis by directly enhancing the secretions of PAI-1. 28 PAI-1 is the principal inhibitor of fibrinolysis and may contribute to the development of thrombosis. 28, 29 From this logic, we speculate that the women in our study population with PCOS between the ages of 18-24 years may have increased levels of PAI-1 compared with the other age groups and thus have the highest probability of VTE. Clinical studies are needed to test this hypothesis. These findings also demonstrate the complex nature of PCOS and its related clinical consequences. For instance, increased cardiovascular risks has been found among women with phenotype A (hyperandrogenism and ovulatory dysfunction) or classic PCOS [15] [16] [17] [18] [19] [20] ; on the other hand, Wiltgen and Spritzer 30 showed that hirsute ovulatory patients with polycystic ovaries (phenotype B) had a lower prevalence of cardiovascular risk factors than those with the classic PCOS phenotype. One would then expect that the highest probability of VTE also would be found among women with phenotype A and the lowest probability among women with phenotype B. However, our findings indicated the opposite.
Another interesting finding was the protective effect of OCP use on VTE among women with PCOS. We believe this finding makes physiologic sense because the estrogenic component of oral contraceptives suppresses the elevated levels of luteinizing hormone among women with PCOS and, thus, ovarian androgen production. In addition, the estrogen component boosts the making of sex hormone-binding globulin by the liver, thereby reducing the amount of plasma testosterone available to bind to androgen receptors. 27 We believe this reduction in androgens likely improves the impaired fibrinolysis present among women with PCOS.
The major strength of this study was in the use of a database that includes a large proportion of the privately insured women in the US population. Also, the group studied was geographically diverse and included women seen both in an inpatient and an outpatient setting, which offered a better estimate of the prevalence of VTE, given that a substantial proportion of patients with VTE are managed in the outpatient setting. 31 A principal limitation of the study related to the purpose of administrative claims databases. Because information in such databases is collected for billing rather than for diagnostic purposes, misclassification of cases might occur due to incomplete or inappropriate coding. For instance, we found lower than expected prevalences for obesity and diabetes among women with PCOS, which may be due to poor reliability of the ICD-9-CM codes for these conditions. In 2008, Quan et al 32 assessed the validity of International Statistical Classification of Diseases, 10th Revision and ICD-9-CM at 4 teaching hospitals in Alberta, Canada, by evaluating agreement between the codes and chart data for 32 clinical conditions. Sensitivity value for obesity was 24.6%, 77.7% for diabetes without chronic conditions, and 63.6% for diabetes with chronic conditions. Poor agreement for conditions such as obesity was postulated to relate to the fact that these conditions may not be explicitly mentioned by a health care provider in clinical notes and may not affect length of stay, health care, or therapeutic treatment. Moreover, coders may intentionally not code these conditions due to the limited amount of time given to code each chart. 32 To handle the possibility of such misclassification, we applied a restriction on how VTE was diagnosed and used an algorithm to define PCOS. Despite these efforts, misclassification still might have been present. For example, since the presence of polycystic ovaries is not an absolute requirement in defining PCOS, an ultrasound may have only been performed in a minority of women; this would have resulted in an underestimation of women with phenotypes B, C, and D.
MarketScan data are obtained from employer-based insurance. Insurance heterogeneity could have resulted in variations in the distribution in other risk factors between the exposed and nonexposed groups that could not have been controlled for in our analysis. However, our findings were comparable with those of studies using clinical information to estimate the prevalence of VTE among women. 6, 33, 34 Ageno et al 35 in 2006 and Ay et al 36 in 2007 showed that metabolic syndrome was a risk factor for developing VTE and, thus, could play a role in VTE among women with PCOS. Despite our large sample size, we did not have enough women with PCOS, metabolic syndrome, and VTE to surmise on a possible connection. This likely was due to the difficulty in defining metabolic syndrome in an administrative data set and the manner in which it was defined in this study. Lack of demographic information also was a limitation of this study in that we could not report on the racial makeup of our study population.
Our findings add to the limited literature on the relationship between the hypercoagulable state of PCOS and thrombosis development. While several studies have shown that women with PCOS are more prone to atherosclerotic issues, [16] [17] [18] [19] [20] 37 we show here, as Mak and Dokras 22 suggested, that women with PCOS have a higher probability of having VTE compared with women without PCOS. 22 We acknowledge that our findings should be interpreted with caution and the relationship between PCOS and VTE should be evaluated further in prospective studies because our data were obtained from administrative data.
VTE and arterial thrombosis have been seen as distinct disease entities because of their differing anatomic locations, risk factors, and clinical presentations. However, a number of studies have shown that idiopathic VTE is associated with an increased risk of subsequent cardiovascular events and that patients with idiopathic VTE have an increased prevalence of asymptomatic atherosclerotic lesions. [38] [39] [40] Because PCOS is associated with atherosclerotic disease, a relationship with venous diseases needs to be considered. Our findings, therefore, do have connotations that might be relevant in clinical settings. The implications of our study for clinicians are that young women with unexplained VTE should be examined for the presence of PCOS. Similarly, women with PCOS should be identified early so prevention strategies can be implemented to lower their risks for cardiovascular conditions and VTE.
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